Cargando…

First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis

BACKGROUND: Anti-drug antibodies (ADAs) can impact on the efficacy and safety of biologicals, today used to treat several chronic inflammatory conditions. Specific patient groups may be more prone to develop ADAs. Rituximab is routinely used for ANCA-associated vasculitis (AAV) and as off-label ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faustini, Francesca, Dunn, Nicky, Kharlamova, Nastya, Ryner, Malin, Bruchfeld, Annette, Malmström, Vivianne, Fogdell-Hahn, Anna, Gunnarsson, Iva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361739/ https://www.ncbi.nlm.nih.gov/pubmed/34389040 http://dx.doi.org/10.1186/s13075-021-02589-6

Ejemplares similares

Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity
por: Faustini, Francesca, et al.
Publicado: (2022)

Occurrence and localization of FOXP3 + cells in kidney biopsies in lupus nephritis and ANCA-associated vasculitis
por: Zickert, Agneta, et al.
Publicado: (2023)

The role of herpesvirus 6A and 6B in multiple sclerosis and epilepsy
por: Dunn, Nicky, et al.
Publicado: (2020)

Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus
por: Wincup, Chris, et al.
Publicado: (2022)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis
por: Vallerskog, Therese, et al.
Publicado: (2006)

Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier
por: Kharlamova, Nastya, et al.
Publicado: (2020)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020)

False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases
por: Kharlamova, Nastya, et al.
Publicado: (2021)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

Proteinase 3 Autoreactivity in Anti‐Neutrophil Cytoplasmic Antibody–associated vasculitis—Immunological versus clinical features
por: Sharma, Ravi K., et al.
Publicado: (2020)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

How is the patient perspective captured in ANCA-associated vasculitis research? An integrative review
por: Granath, Annika, et al.
Publicado: (2023)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
por: Habibi, Mohammad Amin, et al.
Publicado: (2022)

Systemic Lupus Erythematosus and ANCA-Associated Vasculitis Overlap Syndrome: A Case Report
por: Khil, Jaclyn, et al.
Publicado: (2022)

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis
por: Awad, Neveen, et al.
Publicado: (2016)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
por: Treppo, Elena, et al.
Publicado: (2021)

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

Stratified genetic analysis reveals sex differences in MPO-ANCA-associated vasculitis
por: Ekman, Diana, et al.
Publicado: (2023)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

Challenges of defining renal response in ANCA-associated vasculitis: call to action?
por: Odler, Balazs, et al.
Publicado: (2023)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
por: Miyazaki, Yusuke, et al.
Publicado: (2020)

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models
por: McClure, Mark E, et al.
Publicado: (2020)

Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment
por: Nasrallah, Mazen, et al.
Publicado: (2015)

The immunopathology of ANCA-associated vasculitis
por: McKinney, Eoin F., et al.
Publicado: (2014)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-associated vasculitis of the appendix
por: Leaver, Phillip J, et al.
Publicado: (2019)

Comorbidities in ANCA-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-Associated Vasculitis: An Update
por: Almaani, Salem, et al.
Publicado: (2021)

Decreased Neutrophil Apoptosis in Quiescent ANCA-Associated Systemic Vasculitis
por: Abdgawad, Mohamed, et al.
Publicado: (2012)

Induction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab
por: Graham-Brown, M. P. M., et al.
Publicado: (2016)

Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report
por: Harris, Claire, et al.
Publicado: (2018)

Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
por: Goel, Ruchika, et al.
Publicado: (2021)

Association of NCF1 polymorphism with systemic lupus erythematosus and systemic sclerosis but not with ANCA-associated vasculitis in a Japanese population
por: Yokoyama, Nozomi, et al.
Publicado: (2019)

The genomic landscape of ANCA-associated vasculitis: Distinct transcriptional signatures, molecular endotypes and comparison with systemic lupus erythematosus
por: Banos, Aggelos, et al.
Publicado: (2023)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
por: Wallace, Zachary S., et al.
Publicado: (2019)

IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment
por: Zickert, Agneta, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0ib50qle95rppec182lash6409